Prévisions du marché européen des services de pharmacocinétique jusqu\'en 2031 - Analyse régionale - par type de médicament (petite molécule, grande molécule et vaccins), type de service (études précliniques ADME et humaines, analyse et rapports PK/PD, simulations de dosage, analyse des risques et autres), application thérapeutique (oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires et autres) et utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres)
L\'externalisation des services de pharmacocinétique aux CRO stimule le marché européen des services de pharmacocinétique
L\'externalisation des services de pharmacocinétique aux organismes de recherche sous contrat (CRO) offre plusieurs avantages aux fabricants et aux sponsors de médicaments. Ils peuvent fonctionner de manière rentable en optant pour ces services. De plus, ils peuvent se concentrer sur le travail flexible et l\'évolutivité de leurs opérations principales, tout en obtenant des délais d\'exécution rapides. L\'externalisation aide les sociétés pharmaceutiques à se concentrer sur la commercialisation des produits tout en mettant en œuvre des mesures de renforcement des capacités, de réduction des coûts et de gestion des données. Le processus de découverte de médicaments est complexe et toute erreur ou résultat erroné peut entraîner des coûts importants et retarder le processus. Les CRO emploient des scientifiques et des chercheurs expérimentés qui possèdent une expertise en pharmacocinétique et dans d\'autres domaines. Ainsi, ils offrent aux sociétés pharmaceutiques un accès à leur expertise, éliminant ainsi le besoin d\'investir dans l\'embauche de ces travailleurs qualifiés ou de fournir une formation supplémentaire pour les constituer. Par conséquent, les petites entreprises avec des candidats médicaments prometteurs mais des ressources limitées et les grandes entreprises impliquées dans la diversification de leurs opérations optent pour des services de recherche clinique fournis par des CRO bien organisées, ce qui renforce le marché européen des services de pharmacocinétique.
Aperçu du marché européen des services de pharmacocinétique
Le marché européen des services de pharmacocinétique est segmenté en Allemagne, France, Royaume-Uni, Espagne, Italie et reste de l\'Europe. Des pays comme l\'Allemagne et l\'Italie devraient représenter une part importante du marché dans la région, et des pays comme la France, le Royaume-Uni et l\'Espagne sont susceptibles d\'avoir des opportunités de croissance pour les services de pharmacocinétique. Le marché européen des services de pharmacocinétique devrait croître dans les années à venir avec le nombre croissant d\'essais cliniques pour le développement de nouveaux médicaments et l\'adoption croissante de modèles in vivo et in vitro pour comprendre la variabilité de la pharmacocinétique.
Marché européen des services de pharmacocinétique Chiffre d\'affaires et prévisions jusqu\'en 2031 (en millions de dollars américains)
Segmentation du marché européen des services de pharmacocinétique
Le marché européen des services de pharmacocinétique est classé en type de médicament, type de service, application thérapeutique, utilisateur final et pays.
En fonction du type de médicament, le marché européen des services de pharmacocinétique est segmenté en petites molécules, grosses molécules et vaccins. Le segment des petites molécules détenait la plus grande part de marché en 2023.
En termes de type de service, le marché européen des services de pharmacocinétique est classé en études précliniques ADME et humaines, analyse et rapports PK/PD, simulations de dosage, analyse des risques, etc. Le segment des études précliniques ADME et humaines détenait la plus grande part de marché en 2023.
Par application thérapeutique, le marché européen des services de pharmacocinétique est segmenté en oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires, etc. Français Le segment de l\'oncologie détenait la plus grande part de marché en 2023.
Par utilisateur final, le marché européen des services de pharmacocinétique est segmenté en sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres. Le segment des organismes de recherche sous contrat détenait la plus grande part de marché en 2023.
Par pays, le marché européen des services de pharmacocinétique est segmenté en Allemagne, France, Royaume-Uni, Italie, Espagne et reste de l\'Europe. La France a dominé la part de marché européenne des services de pharmacocinétique en 2023.
Charles River Laboratories International Inc ; Eurofins Scientific SE ; Evotec SE ; Certara Inc. ; Parexel International Corp ; Thermo Fisher Scientific Inc. ; Allucent ; PACIFIC BIOLABS ; et SGS SA sont quelques-unes des principales sociétés opérant sur le marché européen des services de pharmacocinétique.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Europe Analysis
5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Europe Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Europe Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Europe Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Europe Pharmacokinetics Services Market - Country Analysis
10.1 Europe
10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Evotec SE
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Certara Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.5 Parexel International Corp
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Thermo Fisher Scientific Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Allucent
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 PACIFIC BIOLABS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 SGS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Europe Pharmacokinetics Services Market Segmentation
Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 26. Glossary of Terms
?
List of Figures
Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.